株式会社の株式価格が0.88に上昇したため,Speo TerraphiticsのCEOとCFOは著しい株式を販売した. Spero Therapeutics' CEO and CFO sold significant shares as the company’s stock price rose to $0.88.

Spero TherapeuticsのCFOのEsther RajaveluとCEOのSath Shuklaは2月5日に多くの株式を売却し,それぞれ2.78%と8.21%の所有権を削減しました. Spero Therapeutics CFO Esther Rajavelu and CEO Sath Shukla sold a significant number of company shares on February 5th, reducing their ownership by 2.78% and 8.21% respectively. SPROの株式価格はその日88%に上昇した. SPRO's stock price increased to $0.88 on that day. 細菌感染や稀な疾患の治療の開発に重点を置く同社は,市場規模は47.81億米ドルで,PE比率は12.53です. The company, focusing on developing treatments for bacterial infections and rare diseases, has a market cap of $47.81 million and a PE ratio of 12.53. 分析官は,国内株式の販売にかかわらず,SPROの正の評価を維持してきた. Despite internal stock sales, analysts have maintained positive ratings on SPRO.